INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (NCT03491683)

🧪 Interventions in This Study

• INO-5401 (BIOLOGICAL)
• INO-9012 (BIOLOGICAL)
• Cemiplimab (BIOLOGICAL)
• Temozolomide (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (21 Sites)

• City of Hope — Duarte, California
• Stanford University, School of Medicine — Palo Alto, California
• University of California, San Francisco — San Francisco, California
• University of Miami - Sylvester Comprehensive Cancer Center — Miami, Florida
• Moffitt Cancer Center — Tampa, Florida
• Emory University School of Medicine — Atlanta, Georgia
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Henry Ford Health System — Detroit, Michigan
• Rutgers University - Cancer Institute of New Jersey — New Brunswick, New Jersey
• New York University Langone Medical Center; Perlmutter Cancer Center — New York, New York
• Icahn School of Medicine at Mount Sinai — New York, New York
• Columbia University Medical Center The Neurological Institute of New York — New York, New York
• New York-Presbyterian Hospital/Weill Cornell Medical Center — New York, New York
• University of North Carolina School of Medicine — Chapel Hill, North Carolina
• Stephenson Cancer Center — Oklahoma City, Oklahoma
• Oregon Health & Science University — Portland, Oregon
• University of Pennsylvania Health System: Penn Medicine — Philadelphia, Pennsylvania
• UPMC Cancer Center Neuro-Oncology; UPMC Cancer Pavilion — Pittsburgh, Pennsylvania
• Texas Oncology — Austin, Texas
• Baylor College of Medicine — Houston, Texas
• Huntsman Cancer Institute — Salt Lake City, Utah

📞 Contact the Study Coordinator

Phone: (800) 826-4673

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Glioblastoma

• Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma — Milwaukee, Wisconsin
• A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. — New York, New York
• A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors — San Francisco, California
• Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma — Phoenix, Arizona
• A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma — Birmingham, Alabama
• Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma — Fairbanks, Alaska

Explore by condition: All Glioblastoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.